Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 6 » default
Therapeutics and Clinical Risk Management
ISSN: 1178-203X
- View all (2241)
- Volume 19, 2023 (24)
- Volume 18, 2022 (104)
- Volume 17, 2021 (134)
- Volume 16, 2020 (134)
- Volume 15, 2019 (154)
- Volume 14, 2018 (271)
- Volume 13, 2017 (188)
- Volume 12, 2016 (217)
- Volume 11, 2015 (210)
- Volume 10, 2014 (113)
- Volume 9, 2013 (57)
- Volume 8, 2012 (47)
- Volume 7, 2011 (59)
- Volume 6, 2010 (66)
- Volume 5, 2009 (102)
- Volume 4, 2008 (148)
- Volume 3, 2007 (126)
- Volume 2, 2006 (47)
- Volume 1, 2005 (40)
Archive: Volume 6, 2010
Reduced exercise capacity in persons with Down syndrome: cause, effect, and management
Goncalo V Mendonca, Fernando D Pereira1 Bo Fernhall
Therapeutics and Clinical Risk Management 2010, 6:601-610
Published Date: 8 December 2010
Experience with alendronate treatment for four years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures
Jun Iwamoto, Yoshihiro Sato, Mitsuyoshi Uzawa, et al
Therapeutics and Clinical Risk Management 2010, 6:593-600
Published Date: 6 December 2010
Effects of recombinant growth hormone replacement and physical rehabilitation in recovery of gross motor function in children with cerebral palsy
Pedro Reimunde, Cristina Rodicio, Natalia López, et al
Therapeutics and Clinical Risk Management 2010, 6:585-592
Published Date: 30 November 2010
A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer
Bevin C English, Caitlin E Baum, David E Adelberg, et al
Therapeutics and Clinical Risk Management 2010, 6:579-583
Published Date: 19 November 2010
Does smoking really protect from recurrent aphthous stomatitis?
Faleh A Sawair
Therapeutics and Clinical Risk Management 2010, 6:573-577
Published Date: 22 November 2010
The emerging role of Clostridium histolyticum collagenase in the treatment of Dupuytren disease
Alexis Thomas, Ardeshir Bayat
Therapeutics and Clinical Risk Management 2010, 6:557-572
Published Date: 4 November 2010
Comparative evaluation of prophylactic single-dose intravenous antibiotic with postoperative antibiotics in elective urologic surgery
Mohammad K Moslemi, Seyed M Moosavi Movahed, Akram Heidari, et al
Therapeutics and Clinical Risk Management 2010, 6:551-556
Published Date: 9 November 2010
New advances in the treatment of gout: review of pegloticase
Mattheus K Reinders, Tim L Th A Jansen
Therapeutics and Clinical Risk Management 2010, 6:543-550
Published Date: 27 October 2010
Portal vein thrombosis in a patient with HCV cirrhosis and combined hemophilia A and thrombophilia V Leiden
Nikos Eleftheriadis, Pantelis Makris
Therapeutics and Clinical Risk Management 2010, 6:539-541
Published Date: 26 October 2010
Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: Focus on delayed-release esomeprazole
Elizabet V Guimarães, Paula VP Guerra, Francisco J Penna
Therapeutics and Clinical Risk Management 2010, 6:531-537
Published Date: 20 October 2010
Emerging clinical role of ranolazine in the management of angina
David S Vadnais, Nanette K Wenger
Therapeutics and Clinical Risk Management 2010, 6:517-530
Published Date: 14 October 2010
Treatment of Cushing disease: overview and recent findings
Tatiana Mancini, Teresa Porcelli, Andrea Giustina
Therapeutics and Clinical Risk Management 2010, 6:505-516
Published Date: 12 October 2010
Role of teriparatide in treatment of glucocorticoid-induced osteoporosis
Arthur N Lau, Jonathan D Adachi
Therapeutics and Clinical Risk Management 2010, 6:497-503
Published Date: 12 October 2010
Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole
April Barbour, Hartmut Derendorf
Therapeutics and Clinical Risk Management 2010, 6:485-495
Published Date: 28 September 2010
Pegylated liposomal doxorubicin in the management of ovarian cancer
Gabriella Ferrandina, Giacomo Corrado, Angelo Licameli, et al
Therapeutics and Clinical Risk Management 2010, 6:463-483
Published Date: 29 September 2010
An improved delivery system for bladder irrigation
Mohammad K Moslemi, Mojtaba Rajaei
Therapeutics and Clinical Risk Management 2010, 6:459-462
Published Date: 30 September 2010
Gastrointestinal stromal tumor (GIST) recurrence following surgery: review of the clinical utility of imatinib treatment
Isabelle Deshaies, Jovenel Cherenfant, Niraj J Gusani, et al
Therapeutics and Clinical Risk Management 2010, 6:453-458
Published Date: 22 September 2010
Intravenous lipid emulsion for treatment of local anesthetic toxicity
M Caroline Kosh, April D Miller, Jill E Michels
Therapeutics and Clinical Risk Management 2010, 6:449-451
Published Date: 24 September 2010
Microbial contamination of nonsterile pharmaceuticals in public hospital settings
Veronica Mugoyela, Kennedy D Mwambete
Therapeutics and Clinical Risk Management 2010, 6:443-448
Published Date: 10 September 2010
Role of tipranavir in treatment of patients with multidrug-resistant HIV
Joshua D Courter, Colleen J Teevan, Michael H Li, et al
Therapeutics and Clinical Risk Management 2010, 6:431-441
Published Date: 23 September 2010
Antibiotic optimization in the difficult-to-treat patient with complicated intra-abdominal or complicated skin and skin structure infections: focus on tigecycline
Wanda C Reygaert
Therapeutics and Clinical Risk Management 2010, 6:419-430
Published Date: 6 September 2010
Growth hormone deficiency and cerebral palsy
Jesús Devesa, Nerea Casteleiro, Cristina Rodicio, et al
Therapeutics and Clinical Risk Management 2010, 6:413-418
Published Date: 7 September 2010
Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide
Jonathan Pinkney, Thomas Fox, Lakshminarayan Ranganath
Therapeutics and Clinical Risk Management 2010, 6:401-411
Published Date: 31 August 2010
Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets
Claudio Gasperini, Serena Ruggieri, Carlo Pozzilli
Therapeutics and Clinical Risk Management 2010, 6:391-399
Published Date: 31 August 2010
Molecular mechanisms and treatment strategies for Dupuytren’s disease
David B O’Gorman, Linda Vi, Bing Siang Gan
Therapeutics and Clinical Risk Management 2010, 6:383-390
Published Date: 27 August 2010
Current and emerging treatments for the management of osteogenesis imperfecta
Elena Monti, Monica Mottes, Paolo Fraschini, et al
Therapeutics and Clinical Risk Management 2010, 6:367-381
Published Date: 24 August 2010
Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentan
Mark J Schuuring, Jeroen C Vis, Marielle G Duffels, et al.
Therapeutics and Clinical Risk Management 2010, 6:359-366
Published Date: 31 August 2010
Correlation of random urine protein creatinine (P-C) ratio with 24-hour urine protein and P-C ratio, based on physical activity: a pilot study
Seyed-Ali Sadjadi, Navin Jaipaul
Therapeutics and Clinical Risk Management 2010, 6:351-357
Published Date: 30 July 2010
Prevalence of impaired glucose tolerance and insulin resistance among obese children and adolescents
Robabeh Ghergherechi, Ali Tabrizi
Therapeutics and Clinical Risk Management 2010, 6:345-349
Published Date: 19 July 2010
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis
Michael Pazianas, Cyrus Cooper, F Hal Ebetino, et al
Therapeutics and Clinical Risk Management 2010, 6:325-343
Published Date: 19 July 2010
Optimal therapy in Gaucher disease
Ozlem Goker-Alpan
Therapeutics and Clinical Risk Management 2010, 6:315-323
Published Date: 5 July 2010
Update on current and emerging treatment options for post-polio syndrome
Elisabeth Farbu
Therapeutics and Clinical Risk Management 2010, 6:307-313
Published Date: 7 July 2010
Antibiotic prescribing practices by dentists: a review
Najla Saeed Dar-Odeh, Osama Abdalla Abu-Hammad, Mahmoud Khaled Al-Omiri, et al
Therapeutics and Clinical Risk Management 2010, 6:301-306
Published Date: 21 June 2010
Analysis of factors influencing the overall effect of racecadotril on childhood acute diarrhea. Results from a real-world and post-authorization surveillance study in Venezuela
Jose Chacón
Therapeutics and Clinical Risk Management 2010, 6:293-299
Published Date: 29 June 2010
Critical appraisal of a fixed combination of esomeprazole and low dose aspirin in risk reduction
Ravi Vachhani, Doumit Bouhaidar, Alvin Zfass, et al
Therapeutics and Clinical Risk Management 2010, 6:287-292
Published Date: 22 June 2010
Review of mifamurtide in the treatment of patients with osteosarcoma
Leo Kager, Ulrike Pötschger, Stefan Bielack
Therapeutics and Clinical Risk Management 2010, 6:279-286
Published Date: 15 June 2010
Continuous epidural infusion of morphine versus single epidural injection of extended-release morphine for postoperative pain control after arthroplasty: a retrospective analysis
Stephanie Vanterpool, Randall Coombs, Karamarie Fecho
Therapeutics and Clinical Risk Management 2010, 6:271-277
Published Date: 10 June 2010
Investigation of clinical interaction between omeprazole and tacrolimus in CYP3A5 non-expressors, renal transplant recipients
Paraskevi F Katsakiori, Eirini P Papapetrou, Dimitrios S Goumenos, et al
Therapeutics and Clinical Risk Management 2010, 6:265-269
Published Date: 4 June 2010
Management of ANCA-associated vasculitis: Current trends and future prospects
Sally Hamour, Alan D Salama, Charles D Pusey
Therapeutics and Clinical Risk Management 2010, 6:253-264
Published Date: 3 June 2010
Intravitreal bevacizumab for macular edema due to proton beam radiotherapy: Favorable results shown after eighteen months follow-up
Eleni Loukianou, Dimitrios Brouzas, Eleni Georgopoulou, et al
Therapeutics and Clinical Risk Management 2010, 6:249-252
Published Date: 21 May 2010
Maximum opening of the mouth by mouth prop during dental procedures increases the risk of upper airway constriction
Hiroshi Ito, Hiroyoshi Kawaai, Shinya Yamazaki, et al
Therapeutics and Clinical Risk Management 2010, 6:239-248
Published Date: 12 May 2010
Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes
Morali D Sharma
Therapeutics and Clinical Risk Management 2010, 6:233-237
Published Date: 10 May 2010
Serum glutathione transferase does not respond to indole-3-carbinol: A pilot study
Daniel R McGrath, Hamid Frydoonfar, Joshua J Hunt, et al
Therapeutics and Clinical Risk Management 2010, 6:225-231
Published Date: 24 May 2010
Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis
Ege Can Serefoglu, Zafer Tandogdu
Therapeutics and Clinical Risk Management 2010, 6:219-223
Published Date: 16 May 2010
Obesity is not associated with contrast nephropathy
Navin Jaipaul, Rendell Manalo, Seyed-Ali Sadjadi, et al
Therapeutics and Clinical Risk Management 2010, 6:213-217
Published Date: 5 May 2010
Equitable access to HCV care in HIV-HCV co-infection can be achieved despite barriers to health care provision
Curtis L Cooper, Celine Giordano, Dave Mackie, et al
Therapeutics and Clinical Risk Management 2010, 6:207-212
Published Date: 20 April 2010
Seven years’ experience with alendronate in postmenopausal Japanese women with osteoporosis
Jun Iwamoto, Yoshihiro Sato, Mitsuyoshi Uzawa, et al
Therapeutics and Clinical Risk Management 2010, 6:201-206
Published Date: 20 April 2010
Critical appraisal and clinical utility of atosiban in the management of preterm labor
Olaleye Sanu, Ronald F Lamont
Therapeutics and Clinical Risk Management 2010, 6:191-199
Published Date: 16 April 2010
Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia
Ayman A Hussein, Stephen J Nicholls
Therapeutics and Clinical Risk Management 2010, 6:183-190
Published Date: 14 April 2010
Ropinirole in restless legs syndrome and periodic limb movement disorder
Daniel Erichsen, Raffaelle Ferri, David Gozal
Therapeutics and Clinical Risk Management 2010, 6:173-182
Published Date: 14 April 2010
Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis
Kenneth P Johnson
Therapeutics and Clinical Risk Management 2010, 6:153-172
Published Date: 12 April 2010
Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis
Linda L Hushaw, Ray Sawaqed, Ghaleb Sweis, et al
Therapeutics and Clinical Risk Management 2010, 6:143-152
Published Date: 16 March 2010
Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis
Nora Koutruba, Jason Emer, Mark Lebwohl
Therapeutics and Clinical Risk Management 2010, 6:123-141
Published Date: 19 March 2010
Update on dexmedetomidine: use in nonintubated patients requiring sedation for surgical procedures
Mohanad Shukry, Jeffrey A Miller
Therapeutics and Clinical Risk Management 2010, 6:111-121
Published Date: 11 March 2010
Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures
Martin E Brown, Rif S El-Mallakh
Therapeutics and Clinical Risk Management 2010, 6:103-109
Published Date: 10 March 2010
Topical calcineurin inhibitors in systemic lupus erythematosus
Christos E Lampropoulos, David P D’Cruz
Therapeutics and Clinical Risk Management 2010, 6:95-101
Published Date: 13 April 2010
Abacavir/lamivudine combination in the treatment of HIV: a review
Geetha Sivasubramanian, Emmanuel Frempong-Manso, Rodger D MacArthur
Therapeutics and Clinical Risk Management 2010, 6:83-94
Published Date: 25 February 2010
Managing opioid-induced constipation in advanced illness: focus on methylnaltrexone bromide
Katri Elina Clemens, Eberhard Klaschik
Therapeutics and Clinical Risk Management 2010, 6:77-82
Published Date: 11 February 2010
Long-term maintenance of pediatric asthma: focus on budesonide/formoterol inhalation aerosol
Peter N Huynh, Lyne G Scott, Kenny YC Kwong
Therapeutics and Clinical Risk Management 2010, 6:65-75
Published Date: 8 February 2010
New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids
Paul F Smith
Therapeutics and Clinical Risk Management 2010, 6:59-63
Published Date: 4 February 2010
Profile of etravirine for the treatment of HIV infection
Alice Tseng, Rodger D MacArthur
Therapeutics and Clinical Risk Management 2010, 6:49-58
Published Date: 21 January 2010
Tenofovir-associated bone density loss
Iwen F Grigsby, Lan Pham, Louis M Mansky, et al
Therapeutics and Clinical Risk Management 2010, 6:41-47
Published Date: 24 December 2009
Current and emerging treatment options for Graves’ hyperthyroidism
Prakash Abraham, Shamasunder Acharya
Therapeutics and Clinical Risk Management 2010, 6:29-40
Published Date: 22 December 2009
A review of the applications of the hydrofiber dressing with silver (Aquacel Ag®) in wound care
Yoav Barnea, Jerry Weiss, Eyal Gur
Therapeutics and Clinical Risk Management 2010, 6:21-27
Published Date: 23 December 2009
Update on the efficacy, effectiveness and safety of artemether–lumefantrine combination therapy for treatment of uncomplicated malaria
Pauline Byakika-Kibwika, Mohammed Lamorde, Harriet Mayanja-Kizza, et al
Therapeutics and Clinical Risk Management 2010, 6:11-20
Published Date: 16 December 2009
Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease
Suzanne Skoda-Smith, Troy R Torgerson, Hans D Ochs
Therapeutics and Clinical Risk Management 2010, 6:1-10
Published Date: 16 December 2009